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Abstract 
Purpose: The purpose of this study was to demonstrate the valence of cyclic RGD peptides, 
P-RGD  (PEG4-c(RGDfK):  PEG4  =  15-amino-4,710,13-tetraoxapentadecanoic  acid),  P-RGD2 
(PEG4-E[c(RGDfK)]2,  2P-RGD4  (E{PEG4-E[c(RGDfK)]2}2,  2P4G-RGD4  (E{PEG4-E[G3- 
c(RGDfK)]2}2: G3 = Gly-Gly-Gly) and 6P-RGD4 (E{PEG4-E[PEG4-c(RGDfK)]2}2) in binding to in-
tegrin v3, and to assess the impact of peptide and linker multiplicity on biodistribution proper-
ties, excretion kinetics and metabolic stability of their corresponding 
111In radiotracers.  
Methods:  Five  new  RGD  peptide  conjugates  (DOTA-P-RGD  (DOTA  =1,4,7,10- 
tetraazacyclododecane-1,4,7,10-tetracetic  acid),  DOTA-P-RGD2,  DOTA-2P-RGD4,  DOTA- 
2P4G-RGD4,  DOTA-6P-RGD4),  and  their 
111In  complexes  were  prepared.  The  integrin  αvβ3 
binding affinity of cyclic RGD conjugates were determined by a competitive displacement assay 
against 
125I-c(RGDyK) bound to U87MG human glioma cells. Biodistribution, planar imaging and 
metabolism studies were performed in athymic nude mice bearing U87MG human glioma xeno-
grafts.  
Results:  The  integrin  v3  binding  affinity  of  RGD  conjugates  follows  the  order  of: 
DOTA-6P-RGD4  (IC50  =  0.3  ±  0.1  nM)  ~  DOTA-2P4G-RGD4  (IC50  =  0.2  ±  0.1  nM)  ~ 
DOTA-2P-RGD4  (IC50  =  0.5  ±  0.1  nM)  >  DOTA-3P-RGD2  (DOTA-PEG4-E[PEG4- 
c(RGDfK)]2: IC50 = 1.5 ± 0.2 nM) > DOTA-P-RGD2 (IC50 = 5.0 ± 1.0 nM) >> DOTA-P-RGD (IC50 
= 44.3 ± 3.5 nM) ~ c(RGDfK) (IC50 = 49.9 ± 5.5 nM) >> DOTA-6P-RGK4 (IC50 = 437 ± 35 nM). The 
fact that DOTA-6P-RGK4 had much lower integrin αvβ3 binding affinity than DOTA-6P-RGD4 
suggests that the binding of DOTA-6P-RGD4 to integrin αvβ3 is RGD-specific. This conclusion is 
consistent  with  the  lower  tumor  uptake  for 
111In(DOTA-6P-RGK4)  than  that  for 
111In(DOTA-6P-RGD4). It was also found that the G3 and PEG4 linkers between RGD motifs have 
a significant impact on the integrin v3-targeting capability, biodistribution characteristics, ex-
cretion kinetics and metabolic stability of 
111In-labeled cyclic RGD peptides.  
Conclusion: On the basis of their integrin v3 binding affinity and tumor uptake of their cor-
responding 
111In radiotracers, it was conclude that 2P-RGD4, 2P4G-RGD4 and 6P-RGD4 are most 
likely bivalent in binding to integrin v3, and extra RGD motifs might contribute to the long tumor 
retention times of 
111In(DOTA-2P-RGD4),
 111In(DOTA-2P4G-RGD4) and 
111In(DOTA-6P-RGD4) 
than that of 
111In(DOTA-3P-RGD3) at 72 h p.i. Among the 
111In-labeled cyclic RGD tetramers 
evaluated in the glioma model, 
111In(DOTA-2P4G-RGD4) has very high tumor uptake with the best 
tumor/kidney  and  tumor/liver  ratios,  suggesting  that 
90Y(DOTA-2P4G-RGD4)  and 
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177Lu(DOTA-2P4G-RGD4)  might  have  the  potential  for  targeted  radiotherapy  of  integrin 
αvβ3-positive tumors. 
Key words: integrin v3, 
111In-labeled cyclic RGD peptides, tumor imaging 
Introduction 
Over last several years, many multimeric cyclic 
RGD  peptides,  such  as  E[c(RGDfK)]2  (RGD2)  and 
E{E[c(RGDfK)]2}2 (RGD4), have been used to develop 
the integrin v3-targeted radiotracers for noninvasive 
imaging  of  rapidly  growing  and  metastatic  tumors 
[1-14].  Multiple  cyclic  RGD  moieties  are  utilized  to 
maximize their integrin v3 binding affinity and the 
radiotracer tumor uptake [9, 15-46]. It was found that 
the radiolabeled (99mTc, 18F, 64Cu, 68Ga and 111In) cyclic 
RGD tetramers have better tumor-targeting capability 
as evidenced by their higher tumor uptake with longer 
tumor retention time than their corresponding dimeric 
and monomeric counterparts [20, 22, 29, 32, 34, 35, 44, 
46]. It was also found that cyclic RGD tetramers, such 
as  DOTA-RGD4  (DOTA  =  1,4,7,10-tetraazacyclodo-
decane-1,4,7,10-tetracetic acid) and DOTA-E{G3-E[G3- 
c(RGDfK)]2}2  (Figure  1:  DOTA-6G-RGD2)  are  likely 
bivalent in binding to integrin v3 even though they 
contain  four  identical  RGD  motifs  [46].  The  key  for 
bivalency  is  the  distance  between  two  RGD  motifs 
[36-38]. For example, RGD2 was monovalent whereas 
PEG4-E[PEG4-c(RGDfK)]2  (3P-RGD2:  PEG4  = 
15-amino-4,7,10,13-tetraoxapentadecanoic  acid)  and 
G3-E[G3-c(RGDfK)]2 (3G-RGD2: G3 = Gly-Gly-Gly) are 
bivalent  because  of  the  increased  distance  between 
two cyclic RGD motifs for simultaneous integrin v3 
binding [38, 45].  
To  further  prove  the  “bivalency  concept”,  we 
prepared  three  new  cyclic  RGD  peptide  tetramers 
(Figure  1:  2P-RGD4,  2P4G-RGD4  and  6P-RGD4).  We 
were  particularly  interested  in  these  three  peptides 
because they contain different number of G3 and PEG4 
linkers between cyclic RGD motifs. The main objective 
of  this  study  was  to  demonstrate  their  valence  in 
binding to integrin v3, and to assess the impact of 
cyclic RGD peptide and linker multiplicity on biodis-
tribution properties, excretion kinetics and metabolic 
stability of 111In radiotracers. In this report, we present 
the  synthesis  and  biological  evaluation  of  RGD  te-
tramer  conjugates,  DOTA-2P-RGD4,  DOTA-2P4G- 
RGD4 and DOTA-6P-RGD4, and their 111In complexes. 
A  whole-cell  competitive  displacement  assay  was 
used to determine their integrin v3 binding affinities 
against 125I-c(RGDyK) bound to U87MG human glio-
ma cells. Biodistribution and planar imaging studies 
performed in the athymic nude mice bearing U87MG 
glioma  xenografts.  For  comparison  purposes,  we 
prepared  and  evaluated  conjugates 
DOTA-PEG4-c(RGDfK) (DOTA-P-RGD), DOTA-PEG4- 
E[c(RGDfK)]2 (DOTA-P-RGD2), and their  111In radio-
tracers using the same in vitro and in vivo assays. In 
addition, we prepared a “scrambled” peptide conju-
gate  DOTA-E{PEG4-E[PEG4-c(RGKfD)]2}2  (DOTA- 
6P-RGK4), which has the same amino acid residues as 
those  in  DOTA-6P-RGD4  using  c(RGKfD)  motifs  in-
stead  of  c(RGDfK),  and  111In(DOTA-6P-RGK4)  to 
demonstrate the RGD-specificity of 111In radiotracers.  
Materials and Methods  
Materials  and  Instruments.  Chemicals  were 
purchased  from  Sigma/Aldrich  (St.  Louis,  MO),  and 
were  used  without  purification.  Cyclic  peptides, 
PEG4-c(RGDfK)  (P-RGD),  PEG4-E[G3-c(RGDfK)]2 
(P2G-RGD2), PEG4-E[PEG4-c(RGDfK)]2 (3P-RGD2) and 
PEG4-E[PEG4-c(RGKfD)]2  (3P-RGK2),  were  all  cus-
tom-made by the Peptides International, Inc. (Louis-
ville,  KY).  DOTA-OSu  (1,4,7,10-tetraazacyclodo-
decane-4,7,10-triacetic acid-1-acetate(N-hydroxysucci-
namide))  was  purchased  from  Macrocyclics  (Dallas, 
TX).  The  Boc-protected  glutamic  acid 
N-hydroxysuccinamide  ester  (Boc-E(OSu)2)  and 
PEG4-E[c(RGDfK)]2 (P-RGD2) were prepared accord-
ing to the methods described in our previous reports 
[23-26].  Syntheses  and  biological  evaluations  of 
DOTA-3P-RGD2  and  111In(DOTA-3P-RGD2)  were  re-
ported in our previous communication [45]. ESI (elec-
tron-spray  ionization)  mass  spectral  data  were  ob-
tained in positive mode using a Finnigan LCQ classic 
mass spectrometer, School of Pharmacy, Purdue Uni-
versity. The MALDI (matrix assisted laser desorption 
ionizations) mass spectral data were collected using 
an Applied Biosystems Voyager DE PRO mass spec-
trometer  (Framingham,  MA),  the  Department  of 
Chemistry, Purdue University.  111InCl3 was obtained 
from Perkin-Elmer Life Sciences (North Billerica, MA). 
The  NH4OAc  buffer  for  111In-labeling  studies  was 
passed over a Chelex-100 column (115 cm) to mini-
mize the trace metal contaminants.  
HPLC Methods. The HPLC method (Method 1) 
used  a  LabAlliance  HPLC  system  equipped  with  a 
UV/vis  detector  (=254  nm)  and  Zorbax  C18 
semi-prep column (9.4 mm x 250 mm, 100 Å pore size; 
Agilent Technologies, Santa Clara, CA). The flow rate 
was 2.5 mL/min with the gradient mobile phase going Theranostics 2011, 1 
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from 90% A (0.1% TFA in water) and 10% (0.1% TFA 
in acetonitrile) at 0 min to 20% B at 5 min and to 40% B 
at 20 min. The radio-HPLC method (Method 2) used 
the LabAlliance HPLC system equipped with a -ram 
IN/US detector (Tampa, FL) and Zorbax C18 column 
(4.6 mm x 250 mm, 300 Å pore size; Agilent Technol-
ogies, Santa Clara, CA). The flow rate was 1 mL/min. 
The mobile phase was isocratic with 90% A (25 mM 
NH4OAc, pH = 6.8) and 10% B (acetonitrile) at 0 – 5 
min, followed by a gradient mobile phase going from 
10% B at 5 min to 20% B at 15 min and to 50% B at 20 
min. 
 
 
Figure  1.  Cyclic  RGD  peptide  tetramer  conjugates:  DOTA-6G-RGD4,  DOTA-6P-RGD4,  DOTA-2P-RGD4  and 
DOTA-2P4G-RGD4. 
 
DOTA-PEG4-c(RGDfK)  (DOTA-P-RGD). 
PEG4-c(RGDfK) (7.1 mg, ~8.3 μmol) and DOTA-OSu 
(5.5  mg,  ~11.0  μmol)  were  dissolved  in  1  mL  of 
anhydrous dimethylformamide (DMF). The pH value 
in the reaction mixture was adjusted to 8.5 – 9.0 using 
diisopropylethylamine (DIEA). The mixture was then Theranostics 2011, 1 
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stirred overnight at room temperature. After addition 
of 3 mL of 100 mM NH4OAc buffer (pH = 7.0), the 
resulting solution was subjected to HPLC-purification 
(Method 1). The fraction at ~ 12.5 min was collected. 
Lyophilization  of  collected  fractions  afforded  conju-
gate  DOTA-P-RGD.  The  yield  was  4.1  mg  (~40%). 
ESI-MS (positive mode): m/z =1237.58 for [M + H]+ (M 
=1236.6 calcd. for C54H88N14O19). 
DOTA-PEG4-[c(RGDfK)]2  (DOTA-P-RGD2). 
PEG4-[c(RGDfK)]2 (1.8 mg, 1.1 μmol) and DOTA-OSu 
(2.1 mg, 4.2 μmol) were dissolved in DMF (1 mL). The 
pH in the reaction mixture was adjusted to 8.5 – 9.0 
using DIEA. The mixture was stirred for 2 h at room 
temperature. Upon addition of 2 mL NH4OAc buffer 
(100  mM,  pH  =  7.0),  the  product  was  separated  by 
HPLC  (Method  1).  Lyophilization  of  the  collected 
fractions  at  ~  16.4  min  afforded  0.9  mg  of 
DOTA-P-RGD2  (~41%)  with  95%  HPLC  purity.  The 
yield was ESI-MS (positive mode) for m/z = 1951.5 for 
[M + H]+, 976.6 for [M + 2H]2+ and 1974.4 for [M + 
Na]+ (M = 1950.2 calcd. for [C86H134N24O28]+). 
Boc-E{PEG4-E[c(RGDfK)]2}2  (Boc-2P-RGD4).  To 
a solution of Boc-E(OSu)2 (1.1 mg, 2.5 mol) in 1 mL of 
DMF were added PEG4-[c(RGDfK)]2 (5.8 mg, 3.4 mol) 
and DIEA (2 drops). The reaction mixture was stirred 
for 2 h at room temperature. The reaction was termi-
nated by adding 3 mL NH4OAc buffer (100 mM, pH = 
7.0). The product was isolated by HPLC (Method 1). 
Lyophilization  of  collected  fractions  at  18.2  min  af-
forded  Boc-2P-RGD4.  The  yield  was  4.5  mg  (~79%). 
ESI-MS (positive mode): m/z = 3344.2 for [M + H]+ and 
1671.9  for  [M  +  2H]2+  (M  =  3342.7  calcd.  for 
[C150H229N41O46]+). 
E{PEG4-E[c(RGDfK)]2}2  (2P-RGD4).  The 
Boc-2P-RGD4 (4.3 mg, 1.3 mol) was dissolved in 2 mL 
of TFA. After standing at room temperature for 5 min, 
TFA was removed. The residue was dissolved in 2 mL 
of  0.1  M  NH4OAc  buffer  (100  mM,  pH  =  7.0).  The 
product was separated by HPLC (Method 1). Lyophi-
lization  of  collected  fractions  at  15.7  min  afforded 
2P-RGD4. The yield was 2.6 mg (~59%). ESI-MS (posi-
tive mode): m/z = 3244.0 for [M + H]+ and 1620.5 for [M 
+ 2H]2+ (M = 3242.6 calcd. for [C145H221N41O44]+). 
DOTA-E{PEG4-E[c(RGDfK)]2}2  (DOTA-2P- 
RGD4). DOTA-OSu (3.3 mg, 6.5 μmol) and 2P-RGD4 
(2.2 mg, 0.7 mol) were dissolved in 1 mL of anhy-
drous DMF. After addition of DIEA (3 drops), the re-
action mixture was stirred for 2 h at room tempera-
ture. Upon addition of 2 mL NH4OAc buffer (100 mM, 
pH = 7.0), the product was isolated by HPLC (Method 
1). Lyophilization of collected fraction at 16.1 min af-
forded  conjugate  DOTA-2P-RGD4  with  >95%  HPLC 
purity. The yield was 1.4 mg (~56%). MALDI-MS: m/z 
=  3626.4  for  [M  +  H]+  (M  =  3626.8  calcd.  for 
[C161H247N45O51]+). 
Boc-E{PEG4-E[Gly3-c(RGDfK)]2}2  (Boc-2P4G- 
RGD4).  To  a  solution  of  Boc-E(OSu)2  (3.8  mg,  8.6 
mol) in DMF (3 mL) were added P2G-RGD2 (20.9 mg, 
11.0  mol) and excess DIEA (3 drops). The mixture 
was stirred for 3 h at room temperature. The reaction 
was terminated by addition of 3 mL NH4OAc buffer 
(100  mM,  pH  =  7.0).  The  product  was  isolated  by 
HPLC  (Method  1).  Lyophilization  of  collected  frac-
tions at 16.3 min afforded Boc-2P4G-RGD4. The yield 
was 9.5 mg (~ 43 %). ESI-MS (positive mode): m/z = 
4028.0  for  [M  +  H]+  (M  =  4027.3  calcd.  for 
[C174H265N53O58]+). 
E{PEG4-E[Gly3-c(RGDfK)]2}2 (2P4G-RGD4). The 
Boc-protected  2P4G-RGD4  (9.0  mg,  2.2  mol)  was 
dissolved  in  2  mL  of  TFA.  After  standing  at  room 
temperature  for  5  min,  TFA  was  removed,  and  the 
residue  was  dissolved  in  2  mL  of  0.1  M  NH4OAc 
buffer (100 mM, pH = 7.0). The product was separated 
from the mixture by HPLC (Method 1). Lyophilization 
of collected fractions at 14.2 min afforded 2P4G-RGD4. 
The yield was 4.0 mg (~46%). ESI-MS (positive mode): 
m/z = 3927.9 for [M + H]+ and 1964.6 for [M + 2H]2+ (M 
= 3927.3 calcd. for [C169H257N53O56]+). 
DOTA-E{PEG4-E[Gly3-c(RGDfK)]2}2 
(DOTA-2P4G-RGD4). DOTA-OSu (5.8 mg, 11.5 mol) 
and 2P4G-RGD4 (3.2 mg, 0.8 mol) were dissolved in 
DMF (2 mL). After addition  of DIEA (2 drops), the 
mixture was stirred for 2 h at room temperature. Upon 
addition of 2 mL NH4OAc buffer (100 mM, pH = 7.0), 
the product was separated by HPLC (Method 1). Ly-
ophilization of collected fraction at 14.9 min afforded 
conjugate DOTA-2P4G-RGD4 with >95% HPLC puri-
ty. The yield was 2.2 mg (~64%). MALDI-MS: m/z = 
4315.4  for  [M  +  H]+  (M  =  4313.6  calcd.  for 
[C185H283N57O63]+). 
Boc-E{PEG4-E[PEG4-c(RGDfK)]2}2  (Boc-6P- 
RGD4).  To  a  solution  of  Boc-E(OSu)2  (2.1  mg,  4.75 
mol) in DMF (2 mL) was added 3P-RGD2 (22 mg, 10.7 
mol).  After  addition  of  excess  DIEA,  the  reaction 
mixture was stirred for 3 h at room temperature. The 
reaction was terminated by addition of 3 mL NH4OAc 
buffer (100 mM, pH = 7.0). The product was separated 
by HPLC (Method 1). Lyophilization of collected frac-
tions  at  18.5  min  afforded  desired  product 
Boc-6P-RGD4.  The  yield  was  15.6  mg  (~76%). 
MALDI-MS: m/z = 4333.8 for [M + H]+ (M = 4331.8 
calcd. for [C194H313N45O66]+). 
E{PEG4-E[PEG4-c(RGDfK)]2}2  (6P-RGD4).  The 
Boc-protected 6P-RGD4 (15.6 mg, 3.6 mol) was dis-
solved in 2 mL of TFA. After standing 5 min at room 
temperature, TFA was removed, and the residue was 
dissolved in 2 mL of NH4OAc buffer (100 mM, pH = 
7.0). The product was separated from the mixture by Theranostics 2011, 1 
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HPLC  (Method  1).  Lyophilization  of  collected  frac-
tions  at  17.3  min  afforded  the  desired  product 
6P-RGD4. The yield was 14.0 mg (~92%). MALDI-MS: 
m/z  =  4233.4  for  [M  +  H]+  (M  =  4231.7  calcd.  for 
[C189H305N45O64]+). 
DOTA-E{PEG4-E[PEG4-c(RGDfK)]2}2  (DOTA- 
6P-RGD4).  DOTA-OSu  (7.7  mg,  15.3  mol)  and 
6P-RGD4 (3.8 mg, 0.9 mol) were dissolved in 1 mL of 
anhydrous DMF. After addition of DIEA (3 drops), the 
reaction mixture was stirred for 2 h at room tempera-
ture. Upon addition of 2 mL NH4OAc buffer (100 mM, 
pH = 7.0), the product was separated from the mixture 
by HPLC (Method 1). Lyophilization of collected frac-
tion at 18.2 min afforded DOTA-6P-RGD4 with >95% 
purity. The yield was 1.8 mg (~43%). MALDI-MS: m/z 
=  4622.7  for  [M  +  H]+  (M  =  4618.1  calcd.  for 
[C205H331N49O71]+). 
Boc-E{PEG4-E[PEG4-c(RGKfD)]2}2  (Boc-6P- 
RGK4). To a solution of the Boc-E(OSu)2 (5.5 mg, 12.5 
mol) in DMF (2 mL) was added 3P-RGK2 (30 mg, 14.6 
mol).  After  addition  of  excess  DIEA,  the  reaction 
mixture was stirred for 3 h at room temperature. The 
reaction was terminated by addition of 3 mL NH4OAc 
buffer (100 mM, pH = 7.0). The product was isolated 
by HPLC (Method 1). Lyophilization of collected frac-
tions  at  18.5  min  afforded  desired  product 
Boc-6P-RGK4.  The  yield  was  15.6  mg  (~49%). 
MALDI-MS: m/z = 4334.9 for [M + H]+ (M = 4331.8 
calcd. for [C194H313N45O66]+). 
E{PEG4-E[PEG4-c(RGKfD)]2}2  (6P-RGK4). 
Boc-6P-RGK4  (15.5  mg,  3.6  mol)  was  dissolved  in 
TFA (2 mL). After 5 min at room temperature, TFA 
was removed, and the residue was dissolved in 2 mL 
of NH4OAc buffer (100 mM, pH = 7.0). The product 
was separated from the mixture by HPLC (Method 1). 
Lyophilization  of  collected  fractions  at  15.8  min  af-
forded  6P-RGK4.  The  yield  was  14.0  mg  (~93%). 
MALDI-MS: m/z = 4233.4 for [M + H]+ (M = 4231.7 
calcd. for [C189H305N45O64]+). 
DOTA-E{PEG4-E[PEG4-c(RGKfD)]2}2  (DOTA- 
6P-RGK4).  DOTA-OSu  (5.0  mg,  10.0  mol)  and 
6P-RGK4 (3.8 mg, 0.9 mol) were dissolved in DMF (1 
mL). After addition  of DIEA (3 drops), the reaction 
mixture was stirred for 2 h at room temperature. Upon 
addition of 2 mL NH4OAc buffer (100 mM, pH = 7.0), 
the product was separated from the mixture by HPLC 
(Method 1). Lyophilization of the collected fraction at 
~18.6 min afforded DOTA-6P-RGK4 with >95% HPLC 
purity. The yield was 2.8 mg (~68%). MALDI-MS: m/z 
=  4622.7  for  [M  +  H]+  (M  =  4618.1  calcd.  for 
[C205H331N49O71]+). 
111In-Labeling. To a clean Eppendorf tube were 
added  200  L  of  the  DOTA  conjugate  solution  (2.5 
mg/mL in 0.1 M NaOAc buffer, pH = 5.5) and 20 L of 
111InCl3 solution (~500 Ci in 0.05 M HCl). The vial 
was heated in a water bath at 100 oC for ~ 15 min. Af-
ter cooling to room temperature, a sample of the re-
sulting  solution  was  analyzed  by  radio-HPLC 
(Method 2). The water-octanol partition coefficients of 
all  111In  radiotracers  were  determined  according  to 
literature methods [40, 41]. The log P values were re-
ported as an average of three independent measure-
ments plus the standard deviation.  
Dose Preparation. For biodistribution studies, all 
new  111In  radiotracers  were  purified  by  HPLC 
(Method 2). Volatiles in the HPLC mobile phase were 
removed under vacuum (~5 mmHg) at room temper-
ature.  Doses  were  prepared  by  dissolving  the  111In 
radiotracer  in  saline  to  70  –  100  Ci/mL.  For  the 
blocking  experiment,  excess  RGD2  was  dissolved  in 
the dose solution to 7.5 mg/mL. For planar imaging 
studies, doses were prepared by dissolving the radio-
tracer (no purification) in saline to ~1 mCi/mL. In all 
cases, the dose solution was filtered with a 0.20  m 
Millex-LG filter before being injected into the animals. 
Each animal was injected with ~0.1 mL of the dose 
solution. 
In Vitro Whole-Cell Integrin v3 Binding As-
say.  The  integrin  binding  affinity  and  specificity  of 
cyclic  RGD  peptides  were  assessed  using 
125I-c(RGDyK)  as  the  integrin-specific  radioligand. 
Briefly,  U87MG  human  glioma  cells  were  grown  in 
Gibco’s Dulbecco’s medium supplemented with 10% 
fetal bovine serum (FBS), 100 IU/ml penicillin and 100 
µg/ml streptomycin (Invitrogen Co, Carlsbad, CA), at 
37 °C in humidified atmosphere containing 5% CO2. 
Filter  multiscreen  DV  plates  were  seeded  with  105 
glioma  cells  in  binding  buffer  and  incubated  with 
125I-c(RGDyK)  in  the  presence  of  increasing  concen-
trations  of  the  RGD  conjugate.  After  removing  the 
unbound  125I-c(RGDyK),  hydrophilic  PVDF  filters 
were collected. The radioactivity was determined us-
ing a -counter (Packard, Meriden, CT). The IC50 val-
ues were calculated by fitting the data by nonlinear 
regression using GraphPad PrismTM (GraphPad Soft-
ware, Inc., San Diego, CA). Experiments were carried 
out twice with triplicate samples. IC50 values are re-
ported as an average plus the standard deviation.  
Animal  Model.  Biodistribution  and  imaging 
studies were performed using the athymic nude mice 
bearing U87MG human glioma xenografts in compli-
ance with NIH animal experiment guidelines (Princi-
ples  of  Laboratory  Animal  Care,  NIH  Publication  No. 
86-23,  revised  1985).  The  animal  protocol  has  been 
approved by the Purdue University Animal Care and 
Use  Committee.  U87MG  cells  were  cultured  in  the 
Minimum Essential Medium, Eagle with Earle’s Bal-
anced Salt Solution (non-essential amino acids sodium Theranostics 2011, 1 
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pyruvate)  (ATCC,  Manassas,  VA)  in  humidified  at-
mosphere  of  5%  carbon  dioxide,  and  were  supple-
mented with 10% fetal bovine serum and 1% penicillin 
and  streptomycin  solution  (GIBCO,  Grand  Island, 
NY).  Female  athymic  nu/nu  mice  were  purchased 
from Harlan (Indianapolis, IN) at 4 – 5 weeks of age. 
Each mouse was implanted subcutaneously with ~5 × 
106 U87MG tumor cells into the left and right upper 
flanks.  In  this  way,  one  could  assess  the  impact  of 
tumor  size  on  the  radiotracer  imaging  quality  in  a 
single  tumor-bearing  mouse.  All  procedures  were 
performed  in  a  laminar  flow  cabinet  using  aseptic 
technique.  Four  weeks  after  inoculation,  the  tumor 
size was 0.1 – 0.4 g, and animals were used for biodis-
tribution and imaging studies.  
Biodistribution  Protocol.  Twenty-five  tu-
mor-bearing mice (20 – 25 g) were randomly divided 
into five groups. Each tumor-bearing mouse was ad-
ministered with ~3 Ci of the 111In radiotracer by tail 
vein injection. Five animals were sacrificed by sodium 
pentobarbital overdose (~200 mg/kg) at 0.5, 1, 4, 24 
and  72  h  postinjection  (p.i.).  Blood  samples  were 
withdrawn from the heart of tumor-bearing mice. The 
tumor and normal organs (brain, eyes, heart, spleen, 
lungs, liver, kidneys, muscle and intestine) were har-
vested, washed with saline, dried with absorbent tis-
sue, weighed, and counted on a Perkin Elmer Wizard 
– 1480 -counter (Shelton, CT). The organ uptake was 
calculated as the percentage of injected dose per gram 
of organ mass (%ID/g) or the percentage of injected 
dose  per  organ  (%ID/organ).  For  the  blocking  ex-
periment, five tumor-bearing athymic nude mice (20 – 
25 g) were used, and each animal was administered 
with ~3 Ci of 111In(DOTA-6P-RGD4) along with ~350 
g (~14 mg/kg) of RGD2. Such a high dose of RGD2 
was used to make sure that the integrin αvβ3 binding 
was  completely  blocked.  At  1  h  p.i.,  all  five  tu-
mor-bearing animals were sacrificed for organ biodis-
tribution.  Biodistribution  data  (%ID/g)  and  tar-
get-to-background (T/B) ratios are reported as an av-
erage plus the standard deviation based on the results 
from five tumor-bearing mice (10 tumors) at each time 
point.  Comparison  between  two  radiotracers  was 
made  using  the  two-way  ANOVA  test  (GraphPad 
Prim 5.0, San Diego, CA). The level of significance was 
set at p < 0.05.  
Tissue Immunohistochemistry. The xenografted 
U87MG  tumor  and  normal  organ  (lung,  liver  and 
kidney)  tissues  were  harvested  from  the  tu-
mor-bearing  mice.  Tissues  were  immediately 
snap-frozen in OCT (optical cutting temperature) so-
lution and cut into 5 μm-thick slices. After thorough 
drying  at  room  temperature,  the  slides  were  fixed 
with  ice-cold acetone for 10 min. The sections were 
then blocked and incubated with anti-integrin β3 an-
tibody (1:100, Santa Cruz) and CD31 antibody (1:100, 
BD  Biosciences)  for  1  h  at  room  temperature.  After 
washing, DyLight 594- and fluorescein isothiocyanate 
(FITC)-conjugated  second  antibodies  (1:500,  Jackson 
ImmunoResearch Inc., West Grove, PA) were added 
to link to integrin β3 or CD31 primary antibody, re-
spectively.  The  fluorescence  was  visualized  with  an 
Olympus  BX51  fluorescence  microscope  (Olympus 
America Inc., Center Valley, PA). Phase contrast pictures 
were also obtained as the histological reference to il-
lustrate the texture of the tumor or normal organ tis-
sue and demonstrate the site of fluorescent staining. 
All the pictures were taken under 100x magnification. 
The same procedure was used to compare integrin β3 
expression levels in the U87MG tumor, kidneys, liver 
and lungs.  
Western  Blot.  The  xenografted  U87MG  glioma 
tumor tissue and normal organ tissues (lung, liver and 
kidney) were excised and homogenized in the RIPA 
buffer. Protease inhibitors were added freshly into the 
lysis buffer before experiments. After sonication, ly-
sates were centrifuged at 12,000 g at 4 °C for 15 min. 
The protein concentration was determined using the 
Bio-Rad Protein Assay Reagent (Bio-Rad Laboratories 
Inc., Hercules, CA). The protein lysates (50 μg) were 
separated by 10% SDS-PAGE and transferred to PVDF 
membranes for detection of integrin 3. The blots were 
incubated in blocking solution consisting of 5% milk 
and 3% BSA in TBS-T for 1 h at room temperature and 
then were immunoblotted at room temperature for 2 h 
with the rabbit polyclonal anti-3 primary antibody 
(1:1000, Cell Signaling Technology, Danvers, MA). The 
anti-rabbit  secondary  antibody  was  incubated  with 
the blots for another 1 h at room temperature. Detec-
tion  by  enzyme-linked  chemiluminescence  was  per-
formed  according  to  the  manufacturer’s  protocol 
(Thermo Fisher Scientific, Rockford, IL).  
Planar Imaging. The imaging studies were per-
formed  on  111In(DOTA-2P-RGD4),  111In(DOTA-2P4G- 
RGD4) and  111In(DOTA-6P-RGD4) using  the athymic 
nude  mice  (n  =  3)  bearing  U87MG  human  glioma 
xenografts. Each tumor-bearing mouse was adminis-
tered with ~100 Ci of 111In radiotracer in 0.1 mL sa-
line via tail vein injection. Animals were anesthetized 
with intraperitoneal injection of ketamine (80 mg/kg) 
and xylazine (19 mg/kg), and were then placed supine 
on  a  single  head  mini  gamma  camera  (Diagnostic 
Services Inc., NJ) equipped with a parallel-hole, me-
dium-energy  and  high-resolution  collimator.  The 
whole-body anterior images were acquired at 0.5, 1, 4, 
24 and 72 h p.i. and stored digitally in a 128 x 128 ma-
trix. The acquisition count limits were set at 200 K. 
After completion of imaging, animals were sacrificed Theranostics 2011, 1 
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by sodium pentobarbital overdose (~200 mg/kg). 
Metabolism. Athymic nude mice were used for 
metabolism  studies.  Each  mouse  was  administered 
with  ~100  Ci  of  111In(DOTA-2P-RGD4), 
111In(DOTA-2P4G-RGD4)  and  111In(DOTA-6P-RGD4) 
via tail vein. The urine samples were collected at 30 
min and 120 min p.i. by manual void, and were mixed 
with equal volume of 50% acetonitrile aqueous solu-
tion. The mixture was centrifuged at 8,000 rpm for 5 
min at room temperature. The supernatant was col-
lected  and  passed  through  a  0.20  micron  Millex-LG 
filter unit to remove any precipitate or particles. The 
filtrate was analyzed by radio-HPLC (Method 2). The 
feces samples were collected at 120 min p.i. and sus-
pended in a mixture of 20% acetonitrile aqueous solu-
tion (2 mL). The resulting mixture was vortexed for 10 
min.  After  centrifuging  at  8,000  rpm  for  5  min,  the 
supernatant was collected and passed through a 0.20 
m Millex-LG filter unit. The filtrate was analyzed by 
radio-HPLC (Method 2). The kidney and liver tissues 
were harvested at 120 min p.i., counted in a Perkin 
Elmer Wizard – 1480 -counter (Shelton, CT) for total 
radioactivity,  and  then  homogenized.  The  homoge-
nate was mixed with 2 mL 20% acetonitrile aqueous 
solution. After centrifuging at 8,000 rpm for 5 min, the 
supernatant was collected and counted on a -counter 
to determine the percentage of radioactivity recovery. 
After filtration through a 0.20 m Millex-LG filter unit 
to remove foreign particles or precipitate, the filtrate 
was  then  analyzed  by  radio-HPLC  (Method  2).  The 
percentage  of  radioactivity  recovery  was  >95%  (by 
-counting) for both urine and feces samples.  
Results 
Cyclic RGD Conjugates. Syntheses of DOTA-P- 
RGD  and  DOTA-P-RGD2  were  straightforward  by 
conjugation of DOTA-OSu with PEG4-c(RGDfK) and 
PEG4-E[c(RGDfK)]2,  respectively,  in  DMF  in  the 
presence of excess DIEA. The key step for successful 
preparation  of  DOTA-2P-RGD4,  DOTA-2P4G-RGD4 
and  DOTA-6P-RGD4  was  the  deprotection  of 
Boc-2P-RGD4, Boc-2P4G-RGD4 and Boc-6P-RGD4, re-
spectively. In general, excess TFA must be removed 
within  10  min  of  the  reaction  in  order  to  minimize 
formation  of  hydrolyzed  products.  Conjugation  of 
2P-RGD4, 2P4G-RGD4 and 6P-RGD4 with DOTA-OSu 
in  anhydrous  DMF  afforded  their  corresponding 
conjugates  DOTA-2P-RGD4,  DOTA-2P4G-RGD4  and 
DOTA-6P-RGD4,  respectively.  DOTA-6P-RGK4  was 
prepared  using  the  identical  procedure  to  that  for 
DOTA-6P-RGD4.  DOTA-6P-RGK4  has  the  identical 
amino  acids,  but  their  sequence  was  scrambled  to 
demonstrate the RGD-specificity of DOTA-6P-RGD4. 
The identities for all new RGD conjugates were con-
firmed  by  ESI-MS  (positive  mode)  or  MALDI-MS. 
Their HPLC purity was >95% before being used for 
111In-labeling and determination of their integrin αvβ3 
binding affinity. 
Integrin αvβ3 Binding Affinity. Figure 2 shows 
the  displacement  curves  of  125I-c(RGDyK)  bound  to 
U87MG  glioma  cells  in  the  presence  of  cyclic  RGD 
peptides. Their IC50 values were obtained from curve 
fitting from Figure 2, and were calculated to be 49.9 ± 
5.5, 44.3 ± 3.5, 5.0 ± 1.0, 1.5 ± 0.2, 0.5 ± 0.1, 0.2 ± 0.1, 0.3 
± 0.1, and 437 ± 35 nM for c(RGDfK), DOTA-P-RGD, 
DOTA-P-RGD2,  DOTA-3P-RGD2,  DOTA-2P-RGD4, 
DOTA-2P4G-RGD4,  DOTA-6P-RGD4  and 
DOTA-6P-RGK4,  respectively.  DOTA-6P-RGK4  has 
much  lower  binding  affinity  than  DOTA-6P-RGD4 
(Figure  2).  The  IC50  of  DOTA-3P-RGD2  was  almost 
identical to that (IC50 = 1.3 ± 0.2 nM) presented in our 
previous report [45].  
Radiochemistry. All 111In radiotracers were pre-
pared by reacting  111InCl3 with the respective DOTA 
conjugates  (DOTA-P-RGD,  DOTA-P-RGD2, 
DOTA-2P-RGD4, DOTA-2P4G-RGD4, DOTA-6P-RGD4 
and DOTA-6P-RGK4) in NH4OAc buffer (100 mM, pH 
=  5.5).  Radiolabeling  was  completed  by  heating  the 
reaction  mixture  at  100  oC  for  ~15  min.  The  radio-
chemical purity was >95% with the specific activity of > 
40  mCi/mol  for  all  111In  radiotracers.  Their  HPLC 
retention times and log P values were listed in Table 1. 
We found that all new 111In radiotracers remain stable 
for more than 72 h in the kit matrix or after HPLC pu-
rification in the presence of 3 mM EDTA.  
Biodistribution Characteristics. Selected biodis-
tribution  data  for  111In(L)  (L  =  DOTA-P-RGD, 
DOTA-P-RGD2, DOTA-2P-RGD4, DOTA-2P4G-RGD4, 
DOTA-6P-RGD4  and  DOTA-6P-RGK4)  are  listed  in 
Tables 2-6. Figure 3 compares their uptake (%ID/g) in 
the tumor and intestine, as well as their tumor/kidney 
and tumor/liver ratios in athymic nude mice (n = 5) 
bearing  U87MG  glioma  xenografts.  The  biodistribu-
tion data and T/B ratios for 111In(DOTA-3P-RGD3) and 
111In(DOTA-6G-RGD4)  were  obtained  from  our  pre-
vious reports [45, 46]. The comparison of their tumor 
uptake will allow us to determine if the cyclic RGD 
tetramers  (DOTA-2P-RGD4,  DOTA-2P4G-RGD4  and 
DOTA-6P-RGD4) are actually tetravalent in binding to 
integrin αvβ3. Theranostics 2011, 1 
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Figure  2.  Competitive inhibition  curves  of 
125I-c(RGDyK)  bound  to  the  U87MG  human  glioma  cells  by c(RGDyK), 
DOTA-P-RGD,  DOTA-P-RGD2,  DOTA-3P-RGD2,  DOTA-2P-RGD4,  DOTA-2P4G-RGD4,  DOTA-6P-RGD4  and 
DOTA-6P-RGK4. Their IC50 values were calculated to be 49.9 ± 5.5, 44.3 ± 3.5, 5.0 ± 1.0, 1.5 ± 0.2, 0.5 ± 0.1, 0.2 ± 0.1, 0.3 
±  0.1,  and  437  ±  35  nM,  respectively.  The  integrin  αvβ3  binding  affinity  follows  the  order:  DOTA-6P-RGD4  ~ 
DOTA-2P4G-RGD4 ~ DOTA-2P-RGD4 > DOTA-3P-RGD2 > DOTA-P-RGD2 > DOTA-P-RGD >> DOTA-6P-RGK4. 
 
Figure 3. Comparison of the uptake (%ID/g) in tumor and intestine, as well as the tumor/kidney and tumor/liver ratios for 
111In(L) (L = DOTA-P-RGD, DOTA-P-RGD2, DOTA-3P-RGD2, DOTA-2P-RGD4, DOTA-2P4G-RGD4, DOTA-6P-RGD4 
and DOTA-6G-RGD4) in the athymic nude mice (n = 5) bearing U87MG glioma xenografts. Biodistribution data and T/B 
ratios for 
111In(DOTA-3P-RGD3) and 
111In(DOTA-6G-RGD4) were obtained from our previous reports [45, 46]. Theranostics 2011, 1 
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Table 1. Radiochemical purity (RCP), HPLC retention time and log P values for 
111In-labeled cyclic RGD peptides.  
Radiotracer  RCP (%)  Retention Time (min)  Log P Value 
111In(DOTA-P-RGD)  > 95  12.4  -3.48 ± 0.12 
111In(DOTA-P-RGD2)  > 92  16.7  -3.22 ± 0.09 
111In(DOTA-3P-RGD2)  > 97  19.6  -4.20 ± 0.21 
111In(DOTA-2P-RGD4)  > 97  19.7  -3.87 ± 0.11 
111In(DOTA-2P4G-RGD4)  > 95  18.4  -3.93 ± 0.09 
111In(DOTA-6P-RGD4)  > 95  19.9  -3.68 ± 0.03 
111In(DOTA-6P-RGK4)  > 95  19.1  -3.61 ± 0.07 
 
Table 2. Selected Biodistribution data of 
111In(DOTA-P-RGD) in athymic nude mice (n = 5) bearing U87MG human glioma 
xenografts.  
%ID/gram  0.5 h  1 h  4 h  24 h  72 h 
Blood  7.39 ± 0.78  0.63 ± 0.03  0.29 ± 0.02  0.06 ± 0.00  0.02 ± 0.01 
Brain  0.27 ± 0.02  0.08 ± 0.02  0.04 ± 0.01  0.03 ± 0.00  0.02 ± 0.00 
Eyes  0.85 ± 0.15  0.48 ± 0.20  0.24 ± 0.01  0.14 ± 0.01  0.10 ± 0.01 
Heart  1.83 ± 0.08  0.40 ± 0.03  0.27 ± 0.03  0.14 ± 0.01  0.09 ± 0.01 
Intestine  2.72 ± 0.50  1.24 ± 0.09  0.91 ± 0.16  0.91 ± 0.33  0.67 ± 0.32 
Kidney  10.94 ± 3.96  3.93 ± 0.09  2.80 ± 0.29  1.92 ± 0.16  1.07 ± 0.11 
Liver  2.79 ± 0.02  1.00 ± 0.08  0.90 ± 0.15  0.47 ± 0.07  0.30 ± 0.07 
Lungs  4.60 ± 0.39  1.01 ± 0.05  0.59 ± 0.01  0.30 ± 0.06  0.16 ± 0.03 
Muscle  1.20 ± 0.35  0.38 ± 0.05  0.27 ± 0.03  0.19 ± 0.04  0.13 ± 0.05 
Spleen  2.91 ± 0.51  0.83 ± 0.10  0.73 ± 0.16  0.63 ± 0.11  0.37 ± 0.05 
U87MG  3.74 ± 0.55  2.54 ± 0.37  2.56 ± 0.40  1.43 ± 0.09  0.74 ± 0.16 
Tumor/Blood  0.52 ± 0.10  4.04 ± 0.70  8.75 ± 1.74  23.72 ± 1.84  40.06 ± 16.44 
Tumor /Brain  13.79 ± 1.72  36.49 ± 13.29  73.08 ± 3.00  50.63 ± 5.24  37.16 ± 10.39 
Tumor /Heart  2.06 ± 0.32  6.36 ± 1.25  9.51 ± 1.48  9.91 ± 0.73  7.62 ± 1.67 
Tumor /Kidney  0.36 ± 0.13  0.65 ± 0.10  0.93 ± 0.20  0.75 ± 0.07  0.67 ± 0.15 
Tumor /Liver  1.34 ± 0.20  2.55 ± 0.42  2.83 ± 0.14  3.10 ± 0.47  2.22 ± 0.48 
Tumor /Lungs  0.83 ± 0.14  2.54 ± 0.45  4.36 ± 0.68  4.90 ± 1.02  4.66 ± 1.02 
Tumor /Muscle  3.46 ± 1.23  6.89 ± 1.55  9.50 ± 1.31  7.90 ± 1.41  7.12 ± 2.37 
 
Table 3. Selected Biodistribution data of 
111In(DOTA-P-RGD2) in athymic nude mice (n = 5) bearing U87MG human glioma 
xenografts.  
%ID/gram  0.5 h  1 h  4 h  24 h  72 h 
Blood  1.13 ± 0.13  0.51 ± 0.09  0.22 ± 0.05  0.07 ± 0.02  0.03 ± 0.01 
Bone  1.52 ± 0.47  1.12 ± 0.14  0.70 ± 0.18  0.79 ± 0.11  0.43 ± 0.06 
Brain  0.11 ± 0.02  0.10 ± 0.02  0.09 ± 0.05  0.06 ± 0.00  0.03 ± 0.01 
Eyes  0.94 ± 0.18  0.82 ± 0.27  0.62 ± 0.22  0.39 ± 0.12  0.20 ± 0.04 
Heart  1.03 ± 0.26  0.69 ± 0.19  0.56 ± 0.15  0.35 ± 0.05  0.14 ± 0.02 
Intestine  4.58 ± 1.49  5.99 ± 2.93  5.88 ± 2.42  2.28 ± 0.78  1.30 ± 0.52 
Kidney  6.36 ± 0.80  4.45 ± 0.21  3.44 ± 0.43  2.79 ± 0.33  1.44 ± 0.13 
Liver  2.84 ± 0.36  2.57 ± 0.42  2.60 ± 0.37  1.51 ± 0.57  0.78 ± 0.34 
Lungs  3.01 ± 0.43  1.91 ± 0.25  1.52 ± 0.75  0.78 ± 0.09  0.33 ± 0.04 
Muscle  1.17 ± 0.26  0.80 ± 0.24  0.70 ± 0.41  0.39 ± 0.11  0.24 ± 0.10 
Spleen  2.01 ± 0.43  1.65 ± 0.13  1.75 ± 0.27  1.47 ± 0.35  0.58 ± 0.09 
U87MG  6.14 ± 1.12  4.95 ± 0.39  4.79 ± 0.61  3.08 ± 0.60  1.55 ± 0.21 
Tumor/Blood  5.43 ± 0.99  9.80 ± 0.78  22.00 ± 2.79  41.34 ± 8.03  53.22 ± 6.41 
Tumor/Kidney  0.96 ± 0.18  1.11 ± 0.09  1.39 ± 0.18  1.10 ± 0.21  1.08 ± 0.14 
Tumor/Liver  2.16 ± 0.39  1.92 ± 0.15  1.84 ± 0.23  2.04 ± 0.40  2.00 ± 0.26 
Tumor/Lungs  2.04 ± 0.37  2.60 ± 0.21  3.15 ± 0.40  3.95 ± 0.77  4.75 ± 0.63 
Tumor/Muscle  5.22 ± 0.95  6.18 ± 0.49  6.88 ± 0.87  7.90 ± 1.53  6.36 ± 0.84 Theranostics 2011, 1 
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Table 4. Selected biodistribution data of 
111In(DOTA-2P-RGD4) in athymic nude mice (n = 5) bearing U87MG human glioma 
xenografts. 
%ID/gram  0.5 h  1 h  4 h  24 h  72 h 
Blood  1.12 ± 0.08  0.31 ± 0.16  0.05 ± 0.02  0.03 ± 0.00  0.02 ± 0.02 
Bone  1.89 ± 0.37  1.83 ± 0.70  1.46 ± 0.69  84 ± 0.34  0.34 ± 0.03 
Brain  0.10 ± 0.01  0.12 ± 0.04  0.07 ± 0.03  0.05 ± 0.01  0.02 ± 0.01 
Eyes  0.87 ± 0.24  1.10 ± 0.22  0.78 ± 0.31  0.39 ± 0.12  0.21 ± 0.12 
Heart  1.12 ± 0.20  0.86 ± 0.22  0.68 ± 0.31  0.31 ± 0.12  0.10 ± 0.01 
Intestine  5.50 ± 1.61  8.98 ± 3.47  7.98 ± 4.47  4.04 ± 1.11  1.03 ± 0.10 
Kidney  8.89 ± 1.28  6.67 ± 1.01  5.68 ± 0.66  4.38 ± 1.10  2.31 ± 0.61 
Liver  2.13 ± 0.74  2.39 ± 0. 97  2.89 ± 1.36  1.56 ± 0.37  0.55 ± 0.05 
Lungs  3.19 ± 0.78  2.47 ± 0.66  1.93 ± 0.77  0.96 ± 0.33  0.33 ± 0.03 
Muscle  0.93 ± 0.29  0.91 ± 0.37  0.72 ± 0.23  0.39 ± 0.26  0.12 ± 0.04 
Spleen  2.36 ± 0.96  2.47 ± 0.66  1.98 ± 0.97  1.22 ± 0.44  0.36 ± 0.02 
U87MG  12.98 ± 5.99  10.66 ± 2.41  8.49 ± 5.28  6.52 ± 3.85  2.87 ± 1.45 
Tumor/Blood  11.60 ± 5.36  34.67 ± 7.84  161.22 ± 100.35  231.33 ± 136.67  192.06 ± 172.1 
Tumor /Kidney  1.46 ± 0.67  1.60 ± 0.27  1.49 ± 0.93  1.46 ± 0.80  1.28 ± 0.59 
Tumor /Liver  6.09 ± 2.81  4.34 ± 1.12  2.93 ± 1.82  4.19 ± 1.04  4.89 ± 1.62 
Tumor /Lungs  4.06 ± 1.88  4.31 ± 0.96  4.40 ± 2.74  6.76 ± 3.99  8.94 ± 5.37 
Tumor /Muscle  13.92 ± 6.43  11.76 ± 3.58  11.83 ± 7.36  16.78 ± 9.92  25.87 ± 15.57 
 
Table 5. Selected biodistribution data of 
111In(DOTA-2P4G-RGD4) in athymic nude mice (n = 5) bearing U87MG human 
glioma xenografts. 
%ID/gram  0.5 h  1 h  4 h  24 h  72 h 
Blood  0.84 ± 0.32  0.13 ± 0.00  0.04 ± 0.00  0.02 ± 0.00  0.03 ± 0.01 
Bone  2.17 ± 0.42  1.76 ± 0.26  1.24 ± 0.16  0.84 ± 0.10  0.42 ± 0.11 
Brain  0.20 ± 0.10  0.07 ± 0.00  0.06 ± 0.02  0.04 ± 0.01  0.04 ± 0.02 
Eyes  1.33 ± 0.23  0.69 ± 0.07  0.66 ± 0.08  0.31 ± 0.01  0.35 ± 0.24 
Heart  1.79 ± 0.31  0.61 ± 0.04  0.57 ± 0.06  0.26 ± 0..02  0.13 ± 0.01 
Intestine  10.36 ± 1.52  4.35 ± 1.13  5.18 ± 1.39  3.78 ± 1.23  1.22 ± 0.61 
Kidney  10.72 ± 2.13  5.57 ± 0.63  4.40 ± 0.63  1.98 ± 0.31  0.85 ± 0.09 
Liver  3.62 ± 0.85  2.36 ± 0.27  1.98 ± 0.39  0.91 ± 0.08  0.25 ± 0.06 
Lungs  4.26 ± 0.78  2.38 ± 0.28  1.91 ± 0.27  1.04 ± 0.04  0.30 ± 0.03 
Muscle  1.64 ± 0.42  0.98 ± 0.11  0.52 ± 0.07  0.30 ± 0.16  0.27 ± 0.07 
Spleen  2.97 ± 0.61  2.02 ± 0.34  1.54 ± 0.25  1.06 ± 0.19  0.54 ± 0.22 
U87MG  11.43 ± 2.92  10.18 ± 1.61  9.50 ± 2.13  5.79 ± 0.67  2.66 ± 0.81 
Tumor/Blood  13.58 ± 3.47  80.74 ± 10.67  218.26 ± 44.57  266.19 ± 59.02  93.96 ± 22.32 
Tumor/Bone  5.27 ± 1.35  5.80 ± 0.65  7.87 ± 2.44  7.02 ± 1.39  6.76 ± 2.74 
Tumor /Kidney  1.07 ± 0.27  1.84 ± 0.26  2.17 ± 0.48  2.96 ± 0.36  3.14 ± 0.84 
Tumor /Liver  3.15 ± 0.81  4.39 ± 1.13  4.79 ± 0.58  6.46 ± 1.33  10.71 ± 1.45 
Tumor /Lungs  2.68 ± 0.69  4.38 ± 1.28  5.07 ± 1.52  5.59 ± 0.63  8.73 ± 1.70 
Tumor /Muscle  6.99 ± 1.79  10.43 ± 1.75  18.07 ± 2.95  24.04 ± 14.24  10.16 ± 2.72 
 
Table 6. Selected biodistribution data of 
111In(DOTA-6P-RGD4) in athymic nude mice (n = 5) bearing U87MG human glioma 
xenografts. 
%ID/gram  0.5 h  1 h  4 h  24 h  72 h 
Blood  0.92 ± 0.06  0.29 ± 0.14  0.20 ± 0.02  0.12 ± 0.02  0.06 ± 0.00 
Bone  1.27 ± 0.23  1.20 ± 0.19  089 ± 0.14  0.88 ± 0.03  0.66 ± 0.01 
Brain  0.15 ± 0.01  0.14 ± 0.03  0.12 ± 0.01  0.08 ± 0.01  0.09 ± 0.06 
Eyes  2.78 ± 2.01  1.43 ± 0.25  1.03 ± 0.14  0.63 ± 0.10  0.48 ± 0.06 
Heart  0.57 ± 0.15  0.78 ± 0.24  0.44 ± 0.04  0.55 ± 0.06  0.37 ± 0.07 
Intestine  11.60 ± 2.52  11.53 ± 6.94  10.36 ± 2.03  8.53 ± 1.88  5.74 ± 1.47 Theranostics 2011, 1 
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Kidney  10.68 ± 1.79  7.21 ± 0.79  5.55 ± 0.88  4.27 ± 0.22  3.10 ± 0.38 
Liver  4.09 ± 0.54  4.01 ± 0.41  2.82 ± 0.54  1.50 ± 0.17  1.23 ± 0.27 
Lungs  4.06 ± 0.88  3.69 ± 0.92  2.18± 0.26  1.62 ± 0.21  0.66 ± 0.08 
Muscle  1.79 ± 0.11  1.04 ± 0.20  0.67 ± 0.09  0.52 ± 0.05  0.23 ± 0.05 
Spleen  2.69 ± 0.63  2.12± 0.20  2.07 ± 0.37  1.67 ± 0.18  1.12 ± 0.15 
U87MG  10.48 ± 1.83  11.08 ± 2.38  8.48 ± 2.75  6.86 ± 1.87  3.04 ± 0.39 
Tumor/Blood  11.32 ± 1.71  46.41 ± 25.60  42.10 ± 16.02  56.45 ± 10.80  52.90 ± 4.95 
Tumor /Kidney  0.99 ± 0.19  1.56 ± 0.41  1.52 ± 0.43  1.60 ± 0.39  1.00 ± 0.21 
Tumor /Liver  2.55 ± 0.21  2.79 ± 0.73  3.04 ± 1.03  3.24 ± 1.02  2.60 ± 0.80 
Tumor /Lungs  2.61 ± 0.33  3.13 ± 1.09  3.86 ± 1.09  4.68 ± 1.72  4.70 ± 0.86 
Tumor /Muscle  5.83 ± 0.80  10.90 ± 2.51  12.56 ± 3.70  13.09 ± 2.85  13.47 ± 3.64 
 
In the glioma model, 111In(DOTA-6P-RGD4) was 
excreted mainly via renal route with >75% of the in-
jected radioactivity recovered from urine and <10% of 
the  injected  radioactivity  from  feces. 
111In(DOTA-6P-RGD4)  had  a  rapid  blood  clearance 
with high tumor/blood ratios (Table 6). It had a high 
initial tumor uptake (10.5 %ID/g at 0.5 h p.i.) with a 
slow  tumor  radioactivity  washout  (t1/2  ~  40  h). 
111In(DOTA-6P-RGD4)  had  a  moderately  low  liver 
uptake with high tumor/liver ratio (Table 6). How-
ever, 111In(DOTA-6P-RGD4) had significant uptake in 
kidneys  and  intestine.  Similar  results  were  also  ob-
tained for  111In(DOTA-6G-RGD4) in the same animal 
model  [46].  111In(DOTA-2P4G-RGD4)  was  also  ex-
creted through the renal route with >80% of the in-
jected  radioactivity  recovered  from  urine  samples. 
111In(DOTA-2P4G-RGD4) had a rapid blood clearance 
with  high  tumor/blood  ratios  (Table  5).  The  initial 
tumor  uptake  of  111In(DOTA-2P4G-RGD4)  (11.4 
%ID/g  at  0.5  h  p.i.)  was  comparable  to  that  of 
111In(DOTA-6P-RGD4) (10.5 %ID/g at 0.5 h p.i.) within 
the  experimental  error;  but  its  tumor  radioactivity 
washout  was  slightly  faster  with  t1/2  being  ~35  h. 
111In(DOTA-2P4G-RGD4)  also  showed  high  tu-
mor/muscle ratio (Table 5), and a rapid liver clear-
ance (3.6 and 0.25 %ID/g at 0.5 and 72 h p.i., respec-
tively). As a result,  111In(DOTA-2P4G-RGD4) has the 
highest  tumor/liver  ratio  at  72  h  p.i.  (Figure  3). 
111In(DOTA-2P4G-RGD4)  also  had  very  high  initial 
intestine uptake; but it was much lower (p <0.01) than 
that of  111In(DOTA-6P-RGD4) at >1 h p.i. The tumor 
uptake  of  111In(DOTA-2P-RGD4)  was  also  high  and 
close to that of  111In(DOTA-6P-RGD4) over the 72 h 
period (Figure 3). Its intestine uptake was comparable 
to  that  of  111In(DOTA-6P-RGD4)  within  the  experi-
mental errors (Figure 3). 111In(DOTA-2P-RGD4) had a 
rapid  clearance  from  normal  organs,  such  as  the 
blood,  kidneys  and  liver.  The  tumor/liver  and  tu-
mor/kidney ratios of 111In(DOTA-2P-RGD4) were well 
comparable  to  those  obtained  for 
111In(DOTA-6P-RGD4)  and  111In(DOTA-6G-RGD4) 
(Figure 3).  
It  seems  that  111In(DOTA-2P-RGD4), 
111In(DOTA-2P4G-RGD4)  and  111In(DOTA-6P-RGD4) 
might  have  higher  tumor  uptake  than 
111In(DOTA-3P-RGD2)  over  the  first  24  h,  but  their 
tumor uptake differences were not significant within 
the experimental error (p > 0.05). The 72 h tumor up-
take  follows  the  general  order  of 
111In(DOTA-6P-RGD4)  (3.04  %ID/g)  > 
111In(DOTA-2P-RGD4)  (2.87  %ID/g)  ~ 
111In(DOTA-2P4G-RGD4)  (2.66  %ID/g)  > 
111In(DOTA-3P-RGD2) (2.18 %ID/g), which is similar 
to  the  trend  of  integrin  αvβ3  binding  affinity  of 
DOTA-6P-RGD4  (IC50  =  0.3  ±  0.1  nM)  ~ 
DOTA-2P4G-RGD4  (IC50  =  0.2  ±  0.1  nM)  ~ 
DOTA-2P-RGD4  (IC50  =  0.5  ±  0.1  nM)  > 
DOTA-3P-RGD2 (IC50 = 1.5 ± 0.2 nM). Among the 111In 
radiotracers  evaluated  in  this  animal  model, 
111In(DOTA-6G-RGD4) had the highest uptake in the 
tumor and intestine (Figure 3) at 72 h p.i. The half-life 
of 111In(DOTA-6G-RGD4) in the tumor was estimated 
to  be  60  h.  In  contrast,  111In(DOTA-3P-RGD2)  and 
111In(DOTA-2P4G-RGD4) had low uptake in the intes-
tine, kidneys and liver over the 72 h period. This was 
particularly  true  at  >  24  h  p.i.  As  a  result, 
111In(DOTA-3P-RGD2)  and  111In(DOTA-2P4G-RGD4) 
had  the  tumor/kidney  and  tumor/liver  ratios  that 
were  significantly  better  (p  <  0.05)  than  those  of 
111In(DOTA-6G-RGD4)  and  111In(DOTA-6P-RGD4) 
during that period of time (Figure 3).  
As expected, 111In(DOTA-P-RGD) had the lowest 
tumor uptake (3.7 and 0.7 %ID/g at 0.5 and 72 h p.i., 
respectively)  among  111In  radiotracers  evaluated  in 
this study. 111In(DOTA-P-RGD2) had a relatively high 
tumor uptake (6.1 at 0.5 h p.i.), but it had a significant 
washout from the tumor with uptake values being 4.9, 
4.8, 3.1 and 1.6 %ID/g at 1, 4, 24 and 72 h p.i., respec-
tively.  The  tumor  uptake  follows  the  trend  of 
111In(DOTA-3P-RGD2)  >  111In(DOTA-P-RGD2)  > 
111In(DOTA-P-RGD),  which  is  completely  consistent 
with the order of their αvβ3 binding affinity (IC50 val-
ue:  DOTA-3P-RGD2  <  DOTA-P-RGD2  <  DOTA-P- 
RGD).  Theranostics 2011, 1 
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Integrin  v3  Specificity.  Figure  4A  compares 
the 60-min organ uptake of  111In(DOTA-6P-RGD4) in 
the  absence/presence  of  excess  RGD2  (~350 
g/mouse). Co-injection of excess RGD2 significantly 
blocked  the  tumor  uptake  of  111In(DOTA-6P-RGD4) 
(0.7 %ID/g with RGD2 vs. 11.1 %ID/g without RGD2 
at  1  h  p.i.).  The  normal  organ  uptake  of 
111In(DOTA-6P-RGD4) was also blocked by the pres-
ence  of  excess  RGD2.  For  example,  the  uptake  of 
111In(DOTA-6P-RGD4)  in  the  eyes,  heart,  intestine, 
liver, lungs and spleen was 1.4, 0.8, 11.5, 4.0, 3.7 and 
2.1 %ID/g, respectively, without excess RGD2, while 
its uptake values in the same organs were 0.1, 0.4, 0.5, 
0.7,  1.2,  and  0.5  %ID/g,  respectively,  with  excess 
RGD2. Similar properties were also observed for other 
radiolabeled (99mTc, 64Cu and 111In) cyclic RGD dimers 
[18, 25, 36-38, 43, 45] and tetramers [20, 31, 46]. 
 
 
Figure  4. A: Comparison of the 60-min biodistribution 
data of 
111In(DOTA-6P-RGD4) in the athymic nude mice (n 
= 5) bearing U87MG human glioma xenografts in the ab-
sence/presence of excess RGD2 to demonstrate its integrin 
αvβ3–specificity. B: Comparison of the 60-min biodistribu-
tion  data  of 
111In(DOTA-6P-RGD4)  and 
111In(DOTA-6P-RGK4) in the athymic nude mice (n = 5) 
bearing  U87MG  glioma  xenografts  to  demonstrate  the 
RGD-specificity. 
RGD Specificity. Figure 4B compares the 60-min 
uptake  of  111In(DOTA-6P-RGD4)  and 
111In(DOTA-6P-RGK4)  in  the  U87MG  glioma  and 
normal  organs.  As  expected,  111In(DOTA-6P-RGK4) 
had much lower (p < 0.01) tumor uptake (0.8 %ID/g) 
than  111In(DOTA-6P-RGD4) (11.1 %ID/g) due to the 
low integrin αvβ3 binding affinity of DOTA-6P-RGK4. 
111In(DOTA-6P-RGK4)  also  had  significantly  lower 
uptake than  111In(DOTA-6P-RGD4) in the normal or-
gans,  such  as  intestine,  kidneys,  liver,  lungs  and 
spleen  (Figure  4B).  Apparently,  replacing  c(RGDfK) 
motifs with c(RGKfD) moieties resulting in a dramatic 
uptake  decrease  in  the  tumor  and  integrin 
αvβ3–positive  organs,  particularly  intestine,  liver, 
lungs and spleen.  
Integrin αvβ3 Expression in Normal Organs. To 
further  understand  the  localization  mechanism  of 
111In radiotracers, the tumor, lung, liver and kidney 
tissues were harvested, and were then double-stained 
for the CD31 and integrin β3 expression. As shown in 
Figure 5A, U87MG glioma had a high integrin β3 ex-
pression  level  on  both  tumor  cells  and  tumor  neo-
vasculature. Most of the blood vessels expressing in-
tegrin β3 were seen from the overlay of positive CD31 
and β3 positive staining. Both the liver and lungs had 
much  lower  integrin  β3  expression  levels  than  the 
U87MG tumor. The integrin β3 expression in kidneys 
was very low, which seems consistent with the results 
from blocking experiment (Figure 4A). These results 
were  further  confirmed  by  the  Western  blot  data 
(Figure 5B).  
Imaging Study. Figure 6 illustrates whole-body 
images of the glioma-bearing mice administered with 
111In(DOTA-2P-RGD4),  111In(DOTA-2P4G-RGD4)  and 
111In(DOTA-6P-RGD4  at  1,  4,  24  and  72  h  p.i.  The 
glioma  tumors  could  be  clearly  visualized  with  ex-
cellent T/B contrast as early as 1 h after injection of 
111In(DOTA-2P-RGD4),  111In(DOTA-2P4G-RGD4)  and 
111In(DOTA-6P-RGD4).  All  three  radiotracers  had  a 
long tumor retention time with t1/2 > 30 h, which was 
completely consistent with the results obtained from 
ex-vivo biodistribution studies (Tables 2-4).  
Metabolic Stability. Figure 7 shows typical ra-
dio-HPLC  chromatograms  of  111In(DOTA-2P-RGD4) 
and  111In(DOTA-6P-RGD4) in saline before injection, 
in urine at 30 min and 120 min p.i., and in feces at 120 
min p.i. The radioactivity recovery from the urine and 
feces samples was >95% in both cases. Attempts to 
extract radioactivity from the liver and kidneys were 
not  successful  due  to  very  limited  radioactivity  ac-
cumulation in both organs. There was little metabo-
lism detected in the urine or feces samples over the 2 h 
study  period  for  111In(DOTA-2P-RGD4). 
111In(DOTA-2P4G-RGD4) had the same metabolic sta-Theranostics 2011, 1 
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bility as 111In(DOTA-2P-RGD4). 111In(DOTA-6P-RGD4) 
was able to maintain its integrity during its excretion 
via the renal route. However, there was a significant 
metabolism during its excretion via the hepatobiliary 
route.  As  a  matter  of  fact,  only  ~45%  of 
111In(DOTA-6P-RGD4)  remained  intact  in  the  feces 
sample.  The  metabolic  instability  was  also  reported 
for 111In(DOTA-6G-RGD4) [46].  
 
 
Figure 5. A: Representative microscopic fluorescence images of the organ tissues (U87MG glioma, lung, liver and kidney) 
obtained from the U87MG tumor-bearing mice. For β3 staining (red), frozen tissue slices were incubated with a β3 primary 
antibody followed by a DyLight 594-conjugated secondary antibody. For CD31 staining (green), slices were incubated with 
a CD31 primary antibody followed by a FITC-conjugated secondary antibody (×100). Yellow color indicates the overlay of 
integrin β3 and CD31. Phase contrast pictures were shown as histological reference. B: Western blot results showing 
expression of integrin 3 in U87MG glioma, lungs, liver and kidneys obtained from the U87MG tumor-bearing mice. Theranostics 2011, 1 
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Figure 6. The whole-body planar images of the tumor-bearing mice (bearing U87MG human glioma xenografts) adminis-
tered with ~100 Ci of 
111In(DOTA-3P-RGD2) (top), 
111In(DOTA-2P-RGD4) (middle) and 
111In(DOTA-6P-RGD4) (bottom) 
to illustrate the long tumor retention times of 
111In-labeled cyclic RGD tetramers. Arrows indicate the presence of tumors. Theranostics 2011, 1 
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Figure 7. Representative radio-HPLC chromatograms of 
111In(DOTA-2P-RGD4) (left) and 
111In(DOTA-6P-RGD4) (right) in 
saline before injection, in urine at 30 min and 120 min p.i., and in feces at 120 min p.i. Each mouse was administered with 
~100 Ci radiotracer. 
111In(DOTA-2P4G-RGD4) has the same metabolic stability in the same animal model. 
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Discussion 
In  this  study,  we  successfully  prepared  111In 
complexes of DOTA-P-RGD, DOTA-P-RGD2, DOTA- 
2P-RGD4,  DOTA-2P4G-RGD4  and  DOTA-6P-RGD4. 
We found that their integrin αvβ3 binding affinity fol-
lows the order: DOTA-6P-RGD4 ~ DOTA-2P4G-RGD4 
~ DOTA-2P-RGD4 > DOTA-P-RGD2 > DOTA-P-RGD 
(Figure  2).  Previously,  we  showed  that 
DOTA-3P-RGD2 binds to the integrin αvβ3 on U87MG 
glioma cells in a bivalent fashion due to the increased 
distance (38 bonds excluding lysine residues) between 
two  cyclic  RGD  motifs  [38,  45].  This  study  further 
confirms this observation. For example, the integrin 
v3 binding affinity of DOTA-3P-RGD2 (IC50 = 1.5 ± 
0.2 nM) is significantly higher (p < 0.01) than that of 
both  DOTA-P-RGD  (IC50  =  44.3  ±  3.5  nM)  and 
DOTA-P-RGD2 (IC50 = 5.0 ± 1.0 nM). The bivalency is 
further  supported  by  the  higher  tumor  uptake  of 
111In(DOTA-3P-RGD2) than 111In(DOTA-P-RGD2) and 
111In(DOTA-P-RGD) over the 72 h study period (Fig-
ure 3).  
The  integrin  v3  binding  affinities  of 
DOTA-2P-RGD4,  DOTA-2P4G-RGD4  and 
DOTA-6P-RGD4 are only marginally higher than that 
of  DOTA-3P-RGD2  (Figure  2),  suggesting  that  they 
might share the same bivalency in binding to the in-
tegrin v3. This conclusion is completely consistent 
with  the  similar  tumor  uptake  of 
111In(DOTA-3P-RGD2),  111In(DOTA-2P-RGD4), 
111In(DOTA-2P4G-RGD4)  and  111In(DOTA-6P-RGD4) 
over  the  first  24  h  (Figure  3).  If  DOTA-2P-RGD4, 
DOTA-2P4G-RGD4  and  DOTA-6P-RGD4  were  tetra-
valent, they would have had much better integrin αvβ3 
binding  affinity  than  DOTA-3P-RGD2  while 
111In(DOTA-2P-RGD4),  111In(DOTA-2P4G-RGD4)  and 
111In(DOTA-6P-RGD4)  would  have  had  significantly 
higher  initial  tumor  uptake  than  that  of 
111In(DOTA-3P-RGD2).  
Two  factors  (bivalency  and  the  “locally  en-
riched” RGD concentration) contribute to the higher 
v3 binding affinity of multimeric RGD peptides than 
that of their monomeric counterpart, and the higher 
tumor  uptake  of  radiolabeled  RGD  dimers  and  te-
tramers than their monomeric analogs [15, 40-46]. The 
concentration factor exists in all dimers and tetramers. 
Because of the short distance between two RGD mo-
tifs in RGD2, it is unlikely for DOTA-P-RGD2 to be 
bivalent [15]. However, once the first one is bonded, 
the “local concentration” of second RGD motif will be 
dramatically increased in the vicinity of neighboring 
integrin  v3  sites.  This  may  explain  why 
DOTA-P-RGD2  has  the  better  integrin  v3  binding 
affinity  (Figure  2)  than  DOTA-P-RGD,  and 
111In(DOTA-P-RGD2) has higher tumor uptake (Figure 
3) than 111In(DOTA-P-RGD). Since IC50 values follow 
the  order  of  DOTA-3P-RGD2  >  DOTA-P-RGD2  > 
DOTA-P-RGD (Figure 2), we believe that both biva-
lency  and  concentration  factors  contribute  to  the 
higher  tumor  uptake  of  111In(DOTA-3P-RGD2)  than 
111In(DOTA-P-RGD) (Figure 3).  
DOTA-3P-RGD2 has two cyclic RGD motifs with 
only  one  possibility  to  achieve  the  bivalency.  In 
DOTA-2P-RGD4,  DOTA-2P4G-RGD4  and 
DOTA-6P-RGD4, however, any two of the four RGD 
motifs can achieve bivalency due to the longer dis-
tance  between  them.  Even  though  DOTA-2P-RGD4, 
DOTA-2P4G-RGD4 and DOTA-6P-RGD4 may not be 
tetravalent, the two extra RGD motifs might contrib-
ute to their better integrin v3 binding affinity than 
that  of  DOTA-3P-RGD2  (Figure  2),  and  the  slightly 
higher  72-h  tumor  uptake  (Figure  3)  for 
111In(DOTA-6P-RGD4)  than  that  for 
111In(DOTA-3P-RGD2). Higher tumor uptake was also 
observed  for  111In(DOTA-6G-RGD4)  than  that  of 
111In(DOTA-3P-RGD3)  at  72  h  p.i.  in  the  same  tu-
mor-bearing animal model [46].  
It is very important to note that the ability of a 
multimeric cyclic RGD peptide to achieve bivalency 
depends largely on the integrin αvβ3 density on tumor 
cells and tumor neovasculature. If the integrin αvβ3 
density is high, the distance between two neighboring 
integrin αvβ3 sites will be short, which makes it easier 
for a multimeric RGD peptide to achieve bivalency. If 
the integrin αvβ3 density is low, the distance between 
two neighboring integrin αvβ3 sites will be long, and it 
might be more difficult for the same multimeric RGD 
peptide to achieve simultaneous integrin  v3 bind-
ing. In that situation, the “concentration factor” will 
be the dominant force contributing to the better in-
tegrin  αvβ3  binding  affinity  of  a  multimeric  cyclic 
RGD peptide than that of its monomeric counterpart, 
and to the higher tumor uptake of the radiolabeled 
cyclic  RGD  multimers  as  compared  to  their  mono-
meric analogs.  
The  integrin  αvβ3-specificity  of 
111In(DOTA-6P-RGD4)  was  demonstrated  by  using 
RGD2 as the blocking agent. The uptake blockage of 
111In(DOTA-6P-RGD4) in the tumor (Figure 4A) sug-
gests that its glioma uptake is indeed mainly integrin 
v3-mediated. The partial blockage of the uptake for 
111In(DOTA-6P-RGD4)  in  eyes,  intestine,  kidneys, 
lungs, liver and spleen indicates that the accumula-
tion of  111In(DOTA-6P-RGD4) in these organs is par-
tially integrin v3-mediated. This conclusion is sup-
ported by the tissue-staining studies (Figure 5A). The 
low  integrin  β3  expression  in  kidneys  (Figure  5B) Theranostics 2011, 1 
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suggests that the radiotracer kidney uptake is caused 
mainly  by  tubular  re-absorption  instead  of  specific 
integrin  αvβ3  binding.  The  RGD-specificity  of 
111In(DOTA-6P-RGD4)  was  demonstrated  by  the  ex-
tremely  low  integrin  αvβ3  binding  affinity  of 
DOTA-6P-RGK4 (Figure 2: IC50 = 437 ± 35 nM), and 
the significantly lower tumor  uptake (Figure 4B) of 
111In(DOTA-6P-RGK4)  as  compared  to  that  of 
111In(DOTA-6P-RGD4).  In  addition, 
111In(DOTA-6P-RGK4) also has low uptake in the in-
testine, kidneys, liver, lungs and spleen, suggesting 
that the high uptake of 111In(DOTA-6P-RGD4) in these 
organs is also RGD-specific.  
Non-invasive imaging of integrin v3 is highly 
desirable for patient selection before anti-angiogenic 
treatment and for more effective monitoring of ther-
apeutic  efficacy  in  the  integrin  v3-positive  cancer 
patients [47-49]. For the tumors to be detectable by 
SPECT (single photon emission tomography) or PET 
(positron emission tomography), they must have suf-
ficient accumulation of radioactivity. In this study, we 
found that small tumors (0.03 – 0.05 g) were clearly 
visualized  (Figure  6)  with  good  contrast  in  the  tu-
mor-bearing  mice  administered  with 
111In(DOTA-2P-RGD4),  111In(DOTA-2P4G-RGD4)  and 
111In(DOTA-6P-RGD4). The tumor detection limit was 
3  –  4  mm  in  diameter  using  a  modified  clinical 
-camera. We believe that the tumor detection limit 
might be < 3 mm using the higher resolution SPECT 
cameras  or  SPECT/CT  systems  with 
111In(DOTA-3P-RGD2),  111In(DOTA-2P-RGD4), 
111In(DOTA-2P4G-RGD4)  and  111In(DOTA-6P-RGD4) 
as radiotracers. From this view point, all these  111In 
radiotracers are useful for the early detection of in-
tegrin v3–positive tumors.  
It is well-established that multimerization of cy-
clic RGD peptides can significantly improve their in-
tegrin  v3-targeting  capability  [9,  15-41].  However 
this  often  leads to  more accumulation of the radio-
labeled RGD multimers in the integrin v3-positive 
organs,  as  evidenced  by  the  higher  uptake  of 
111In(DOTA-2P-RGD4)  and  111In(DOTA-6P-RGD4) 
than 111In(DOTA-3P-RGD2) in the intestine, liver and 
kidneys.  As  a  result,  111In(DOTA-2P-RGD4)  and 
111In(DOTA-6P-RGD4) have the tumor/liver and  tu-
mor/kidney ratios significantly (p < 0.01) lower than 
those of 111In(DOTA-3P-RGD2) (Figure 3). On the basis 
of  tumor-to-background  ratios,  we  believe  that 
111In(DOTA-3P-RGD2)  is  a  better  diagnostic  radio-
tracer  than  111In(DOTA-2P-RGD4)  and 
111In(DOTA-6P-RGD4).  At  this  moment,  we  are  not 
clear  why  111In(DOTA-2P4G-RGD4)  has  lower  (p  < 
0.05) intestine uptake than 111In(DOTA-6P-RGD4) and 
111In(DOTA-6G-RGD4)  (Figure  3)  even  though  they 
share the same four cyclic RGD motifs. However, it is 
clear that the G3 and PEG4 linkers between cyclic RGD 
motifs  have  a  significant  impact  on  biodistribution 
characteristics of 111In-labeled cyclic RGD tetramers.  
For diagnostic radiotracers, the contrast between 
the targeted organ and surrounding tissues is the first 
priority.  For  therapeutic  radiotracers,  however, 
maximal  delivery  of  tumoricidal  radiation  dose  be-
comes  critically  important.  The  radiotracer  with 
longer  retention  time  will  deliver  higher  radiation 
dose to tumors during the same period of time. From 
this viewpoint, DOTA-6G-RGD4 remains the best for 
the  integrin  αvβ3-targeted  therapeutic  90Y  and  177Lu 
radiotracers  since  111In(DOTA-6G-RGD4)  has  the 
longest  retention  time  (t1/2  ~  60  h)  among  four 
111In-labeled RGD tetramers (Figure 3). However, one 
cannot totally ignore its high intestine uptake and low 
tumor/liver ratios over the 72 h period. Considering 
the radiotracer uptake in normal organs (particularly 
intestine and liver), we believe that DOTA-3P-RGD2 
and  DOTA-2P4G-RGD4  have  significant  advantages 
over  DOTA-6P-RGD4  and  DOTA-6G-RGD4  because 
the  intestine  and  liver  uptake  of 
111In(DOTA-3P-RGD2)  and  111In(DOTA-2P4G-RGD4) 
is  significantly  lower  than  that  of 
111In(DOTA-6P-RGD4)  and  111In(DOTA-6P-RGD4) 
(Figure 3). It must be noted that there is always a sub-
tle balance between maximizing the radiation dose to 
tumor cells and minimizing the radiation burden to 
the surrounding normal tissues or organs.  
It  is  interesting  to  point  out  that 
111In(DOTA-2P-RGD4)  is  stable  during  its  renal  and 
hepatobiliary  excretion  over  the  2  h  study  period 
(Figure  7).  In  contrast,  111In(DOTA-6P-RGD4)  has  a 
significant metabolism during its hepatobiliary excre-
tion while it remains relatively unchanged during its 
renal excretion (Figure 7). 111In(DOTA-6G-RGD4) has 
similar metabolic instability except that only 25% of it 
remains intact in the feces samples in the same animal 
model [46]. Although it remains unclear as for what 
causes this metabolic instability, one thing is clear that 
the  linkers  between  RGD  motifs  have  a  significant 
impact on the metabolic stability of 111In-labeled cyclic 
RGD tetramers.  
Conclusion 
In summary, we evaluated five new radiotracers 
111In(L) (L = DOTA-P-RGD, DOTA-P-RGD2, DOTA- 
2P-RGD4, DOTA-2P4G-RGD4 and DOTA-6P-RGD4) to 
explore the effect of peptide and PEG4 linker multi-
plicity  on  their  tumor  uptake  and  T/B  ratios.  We 
found that the addition of two PEG4 linkers between 
two RGD  motifs significantly improves the integrin 
v3-targeting capability of cyclic RGD dimers as ev-Theranostics 2011, 1 
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idenced by their higher integrin v3-binding affinity 
and the high tumor uptake and better T/B ratios of 
their  radiotracers.  We  also  found  that 
DOTA-2P-RGD4,  DOTA-2P4G-RGD4  and  DOTA-6P- 
RGD4 are not tetravalent in binding to integrin v3 
because increasing the RGD multiplicity from dimers 
to  tetramers  didn’t  significantly  improve  the  radio-
tracer’s initial tumor uptake. However, the extra RGD 
motifs  in  DOTA-2P-RGD4,  DOTA-2P4G-RGD4  and 
DOTA-6P-RGD4  might  contribute  to  slightly  higher 
tumor  uptake  of  111In(DOTA-2P-RGD4), 
111In(DOTA-2P4G-RGD4)  and  111In(DOTA-6P-RGD4) 
than that of 111In(DOTA-3P-RGD2) at 72 h p.i. Among 
the  111In-labeled  cyclic  RGD  tetramers  evaluated  in 
this animal model,  111In(DOTA-2P4G-RGD4) has the 
best tumor/kidney and tumor/liver ratios. The com-
bination of its high tumor uptake, long retention time 
and  low  uptake  in  normal  organs  suggests  that 
90Y(DOTA-2P4G-RGD4)  and  177Lu(DOTA-2P4G- 
RGD4)  may  have  the  potential  for  radiotherapy  of 
integrin αvβ3-positive tumors [50]. Evaluations of their 
therapeutic efficacy are still in progress, and the result 
from these studies will be communicated elsewhere.  
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